Nelson Capital Management LLC grew its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 1.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 18,471 shares of the medical research company’s stock after acquiring an additional 217 shares during the quarter. Nelson Capital Management LLC’s holdings in Amgen were worth $4,101,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of the stock. Edgestream Partners L.P. lifted its stake in shares of Amgen by 250.3% in the second quarter. Edgestream Partners L.P. now owns 5,391 shares of the medical research company’s stock worth $1,197,000 after buying an additional 3,852 shares in the last quarter. Oxford Financial Group Ltd. lifted its position in Amgen by 41.1% in the 2nd quarter. Oxford Financial Group Ltd. now owns 3,257 shares of the medical research company’s stock valued at $723,000 after acquiring an additional 949 shares in the last quarter. Personal CFO Solutions LLC boosted its stake in Amgen by 4.1% during the 2nd quarter. Personal CFO Solutions LLC now owns 2,787 shares of the medical research company’s stock valued at $619,000 after purchasing an additional 110 shares during the last quarter. Legacy Capital Group California Inc. increased its holdings in shares of Amgen by 2.9% in the 2nd quarter. Legacy Capital Group California Inc. now owns 3,106 shares of the medical research company’s stock worth $690,000 after purchasing an additional 87 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Amgen by 0.5% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 582,119 shares of the medical research company’s stock worth $129,237,000 after purchasing an additional 2,709 shares during the last quarter. Hedge funds and other institutional investors own 74.44% of the company’s stock.
Insider Buying and Selling at Amgen
In other news, EVP Jonathan P. Graham sold 10,000 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $272.81, for a total value of $2,728,100.00. Following the transaction, the executive vice president now owns 28,078 shares of the company’s stock, valued at $7,659,959.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, EVP Jonathan P. Graham sold 10,000 shares of the stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $272.81, for a total transaction of $2,728,100.00. Following the completion of the transaction, the executive vice president now directly owns 28,078 shares of the company’s stock, valued at $7,659,959.18. The sale was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Amgen Inc purchased 1,764,705 shares of the business’s stock in a transaction on Tuesday, September 19th. The shares were purchased at an average price of $17.00 per share, with a total value of $29,999,985.00. Following the acquisition, the insider now directly owns 35,368,653 shares in the company, valued at $601,267,101. The disclosure for this purchase can be found here. Insiders own 0.46% of the company’s stock.
Analyst Upgrades and Downgrades
Amgen Price Performance
Shares of AMGN stock traded down $3.61 on Friday, hitting $265.39. 2,642,931 shares of the stock traded hands, compared to its average volume of 2,476,674. The company has a debt-to-equity ratio of 7.71, a current ratio of 2.86 and a quick ratio of 2.56. Amgen Inc. has a 52 week low of $211.71 and a 52 week high of $291.60. The firm has a 50 day simple moving average of $269.59 and a two-hundred day simple moving average of $247.35. The firm has a market cap of $142.03 billion, a price-to-earnings ratio of 18.86, a PEG ratio of 2.61 and a beta of 0.58.
Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings results on Tuesday, October 31st. The medical research company reported $4.96 EPS for the quarter, beating analysts’ consensus estimates of $4.65 by $0.31. The business had revenue of $6.90 billion for the quarter, compared to analysts’ expectations of $6.92 billion. Amgen had a return on equity of 165.37% and a net margin of 28.20%. The business’s quarterly revenue was up 3.7% on a year-over-year basis. During the same period last year, the firm earned $4.70 earnings per share. As a group, equities research analysts predict that Amgen Inc. will post 18.65 earnings per share for the current fiscal year.
Amgen Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Friday, November 17th will be paid a $2.13 dividend. The ex-dividend date is Thursday, November 16th. This represents a $8.52 annualized dividend and a yield of 3.21%. Amgen’s payout ratio is 60.55%.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
- Five stocks we like better than Amgen
- Roth IRA Calculator: Calculate Your Potential Returns
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- 5 Top Rated Dividend Stocks to Consider
- MarketBeat Week in Review – 11/13 – 11/17
- Overbought Stocks Explained: Should You Trade Them?
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.